Optimal dosing frequency of pegylated interferon alfa-2b monotherapy for chronic hepatitis C virus infection

Clinical Gastroenterology and Hepatology

Volumn 3, Issue 6, 2005, Pages 610-615

  Lurie, Yoav ^a,e   Rouzier Panis, Regine ^b   Webster, George J M ^c   Dusheiko, Geoffrey M ^c   Laughlin, Mark ^d   Jackson, Mary L ^d   Oren, Ran ^a  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b Centre CAP   (France)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^d MERCK RESEARCH LABORATORIES   (United States)

^e Hepatitis Clinic   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; PEGINTERFERON ALPHA2B; RECOMBINANT ALPHA2B INTERFERON; VIRUS RNA;

ADULT; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; EPISTAXIS; FATIGUE; FEMALE; FLU LIKE SYNDROME; GENOTYPE; HEADACHE; HEPATITIS C; HUMAN; INJECTION SITE REACTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; NONHUMAN; PETECHIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; WEIGHT REDUCTION;

EID: 20444467154     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1542-3565(04)00723-2     Document Type: Article

References (16)

1. B.A. Luxon, M. Grace, D. Brassard Pegylated interferons for the treatment of chronic hepatitis C infection Clin Ther 24 2002 1363 1383
2. NIH Consensus Development Panel. Management of hepatitis C: 2002; June 10-12, 2002. NIH consensus statement http://consensus.nih.gov/cons/116/ 116cdcintro.htm Accessed March 3, 2004.
3. M.P. Manns, J.G. McHutchison, S.C. Gordon International Hepatitis Interventional Therapy Group Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C a randomised trial Lancet 358 2001 958 965
4. M.W. Fried, M.L. Shiffman, K.R. Reddy Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 2002 975 982
5. ® (peginterferon alfa-2b) powder for injection Physicians' desk reference 58th ed 2004 Thomson PDR Montvale, NJ 3064 3069
6. Food and Drug Administration Antiviral Drugs Advisory Committee. Briefing information: an update on the approval of BLA 103949/5002, PEG-Intron™ (peginterferon alfa-2b) Powder for Injection, indicated for use alone or in combination with Rebetol (ribavirin, USP) for the treatment of chronic hepatitis C in patients with compensated liver disease who have not been previously treated with interferon alpha and are at least 18 years of age http://www.fda.gov/ohrms/dockets/ac/01/briefing/3819b1.htm Accessed March 3, 2004.
7. P. Ferenci Weight-based dosing of pegylated interferon-alpha in chronic hepatitis C Just a marketing 'gag'? Dig Liver Dis 35 2003 601 606
8. N.P. Lam, A.U. Neumann, D.R. Gretch Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa Hepatology 26 1997 226 231
9. M.J. Tong, L.M. Blatt, J.G. McHutchison Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics a comparison Hepatology 26 1997 1640 1645
10. A.B. Miller, B. Hoogstraten, M. Staquet Reporting results of cancer treatment Cancer 47 1981 207 214
11. P. Esposito, L. Barbero, P. Caccia PEGylation of growth hormone-releasing hormone (GRF) analogues Adv Drug Deliv Rev 55 2003 1279 1291
12. M.D. Green, H. Koelbl, J. Baselga A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy Ann Oncol 14 2003 29 35
13. G.L. Davis, J.B. Wong, J.G. McHutchison Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C Hepatology 38 2003 645 652
14. K.L. Lindsay, C. Trepo, T. Heintges Hepatitis Interventional Therapy Group A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C Hepatology 34 2001 395 403
15. J.G. McHutchison, T. Poynard, K. Patel Patient body weight and response to interferon alfa-2b monotherapy [abstract 998] Hepatology 34 2001 P421A
16. J.G. McHutchison, M. Manns, K. Patel International Hepatitis Interventional Therapy Group Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C Gastroenterology 123 2002 1061 1069